These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30991036)

  • 1. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
    Colby JM; Patel PC; Fu DY; Rutherford NJ
    Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology.
    Leclercq M; Soichot M; Delhotal-Landes B; Bourgogne E; Gourlain H; Mégarbane B; Labat L
    J Anal Toxicol; 2020 Mar; 44(2):200-205. PubMed ID: 31384953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS/MS gold standard.
    Abou El Hassan M; Colantonio D; Likhodii S; Nassar BA
    Clin Biochem; 2021 Jul; 93():99-103. PubMed ID: 33844982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine.
    Gingras M; Laberge MH; Lefebvre M
    J Anal Toxicol; 2010 Mar; 34(2):78-83. PubMed ID: 20223099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
    Begeman A; Franssen EJF
    Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-positive urine opiate screening associated with fluoroquinolone use.
    Zacher JL; Givone DM
    Ann Pharmacother; 2004 Sep; 38(9):1525-8. PubMed ID: 15252190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
    Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
    Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do all screening immunoassay positive buprenorphine samples need to be confirmed?
    Saleem M; Martin H; Tolya A; Coates P
    Ann Clin Biochem; 2017 Nov; 54(6):707-711. PubMed ID: 28121168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine.
    Shaikh S; Hull MJ; Bishop KA; Griggs DA; Long WH; Nixon AL; Flood JG
    J Anal Toxicol; 2008 Jun; 32(5):339-43. PubMed ID: 18544218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory.
    Johnson-Davis KL; Sadler AJ; Genzen JR
    J Anal Toxicol; 2016 Mar; 40(2):97-107. PubMed ID: 26668238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. False-Positive Amphetamines in Urine Drug Screens: A 6-Year Review.
    Pope JD; Drummer OH; Schneider HG
    J Anal Toxicol; 2023 Mar; 47(3):263-270. PubMed ID: 36367744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinolones and false-positive urine screening for opiates by immunoassay technology.
    Baden LR; Horowitz G; Jacoby H; Eliopoulos GM
    JAMA; 2001 Dec; 286(24):3115-9. PubMed ID: 11754677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin interference with opiate urine drug screen.
    Straley CM; Cecil EJ; Herriman MP
    Pharmacotherapy; 2006 Mar; 26(3):435-9. PubMed ID: 16503726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine.
    Schubert B; Pitterl F; Saxl B; Pavlic M
    J Anal Toxicol; 2019 Jun; 43(5):364-368. PubMed ID: 30753557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation and Utility of Drug of Abuse Screening Immunoassays: Insights From Laboratory Drug Testing Proficiency Surveys.
    Krasowski MD; McMillin GA; Melanson SEF; Dizon A; Magnani B; Snozek CLH
    Arch Pathol Lab Med; 2020 Feb; 144(2):177-184. PubMed ID: 31313960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
    Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
    J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consumption of the Sugar Substitute Stevia Leads to Cross-Reactivity of CEDIA® Buprenorphine II Immunoassay.
    Plattner S; Pavlic M; Pitterl F; Schubert B
    J Anal Toxicol; 2021 Nov; 45(9):1052-1057. PubMed ID: 33104778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
    Mina A
    J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride.
    Birch MA; Couchman L; Pietromartire S; Karna T; Paton C; McAllister R; Marsh A; Flanagan RJ
    J Anal Toxicol; 2013 May; 37(4):233-6. PubMed ID: 23471956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.
    Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD
    BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.